神威藥業(02877.HK)中期業績 ：線上銷售大增280.4%，所有劑形全線增長，中期息39分
格隆匯8月31日丨神威藥業(02877.HK)公佈中期業績，截至2021年6月30日止6個月，集團營業額為人民幣15.54億元，比去年同期上升30.6%；期內溢利為人民幣3.08億元，比去年同期上升21.6%；每股盈利為人民幣41分，宣派每股中期股息人民幣39分。
集團於2021年首六個月期內毛利率為73.8%，比去年同期73.6%略有上升，主要是由於較高毛利率的口服類產品利潤貢獻比例持續增加。
集團於2021年上半年聚焦佈局重點產品，全面加強終端覆蓋和投入，大部分重點產品於期內獲得可觀的銷售增長，注射液產品整體恢復增長勢頭。
新冠肺炎疫情爆發以來，國家政府多次強調堅持中西醫結合治療，數箇中藥注射液(包括集團有生產的參麥注射液)亦被列入了《新型冠狀病毒肺炎診療方案(試行第七版)》，突出了中藥注射液的有效性及安全性，中藥注射液市場需求逐漸回暖，集團同時亦積極優化注射液產品組合，令今年上半年整體注射液產品銷售額同比增長29.9%。
集團繼續以拓展口服制劑新增長點為重點發展策略，口服產品2021年上半年整體銷售額同比增長31.1%，於2021年上半年軟膠囊、顆粒劑和中藥配方顆粒產品銷售額較去年同期分別上升7.6%、61.8%及34.1%，口服產品銷售比例已達集團整體銷售額的59.1%。
截至2021年6月30日，集團共有超過400個藥品生產批文，超過100個為集團常規生產產品，分佈17個治療領域，其中23個為集團獨家產品，18個被列入國家基本藥物目錄，共有23種產品獲被納入國家低價藥品清單目錄、16種產品被納入省低價藥品清單目錄，及3種產品被納入急救藥品目錄內。於2021年首六個月，集團繼續專注推動其藥效顯着及高質量的現代中藥產品。
此外，集團互聯網數字營銷團隊2021年上半年完成了線上銷售約人民幣7900萬元，比去年同期增長280.4%。其中通過B2B第三方網上平台銷售的佔比79.3%，而通過B2C網上電商銷售的佔比約20.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
